1.

The prior infection with SARS-CoV-2 study (PICOV) in nursing home residents and staff - study protocol description and presentation of preliminary findings on symptoms.

2.

The prior infection with SARS-CoV-2 study (PICOV) in nursing home residents and staff - study protocol description and presentation of preliminary findings on symptoms.

3.

The prior infection with SARS-CoV-2 study (PICOV) in nursing home residents and staff - study protocol description and presentation of preliminary findings on symptoms.

4.

The prior infection with SARS-CoV-2 study (PICOV) in nursing home residents and staff - study protocol description and presentation of preliminary findings on symptoms.

1.

SARS-CoV-2 infections and impact of the COVID-19 pandemic in pregnancy and breastfeeding: Results from an observational study in primary care in Belgium

2.

SARS-CoV-2 infections and impact of the COVID-19 pandemic in pregnancy and breastfeeding: Results from an observational study in primary care in Belgium

3.

SARS-CoV-2 infections and impact of the COVID-19 pandemic in pregnancy and breastfeeding: Results from an observational study in primary care in Belgium

4.

SARS-CoV-2 infections and impact of the COVID-19 pandemic in pregnancy and breastfeeding: Results from an observational study in primary care in Belgium

5.

SARS-CoV-2 infections and impact of the COVID-19 pandemic in pregnancy and breastfeeding: Results from an observational study in primary care in Belgium

6.

SARS-CoV-2 infections and impact of the COVID-19 pandemic in pregnancy and breastfeeding: Results from an observational study in primary care in Belgium

7.

SARS-CoV-2 infections and impact of the COVID-19 pandemic in pregnancy and breastfeeding: Results from an observational study in primary care in Belgium

8.

SARS-CoV-2 infections and impact of the COVID-19 pandemic in pregnancy and breastfeeding: Results from an observational study in primary care in Belgium

9.

SARS-CoV-2 infections and impact of the COVID-19 pandemic in pregnancy and breastfeeding: Results from an observational study in primary care in Belgium

1.

Additional file 1 of COVID-19: first long-term care facility outbreak in the Netherlands following cross-border introduction from Germany, March 2020

2.

Additional file 1 of COVID-19: first long-term care facility outbreak in the Netherlands following cross-border introduction from Germany, March 2020

3.

Additional file 1 of COVID-19: first long-term care facility outbreak in the Netherlands following cross-border introduction from Germany, March 2020

4.

Additional file 1 of COVID-19: first long-term care facility outbreak in the Netherlands following cross-border introduction from Germany, March 2020

1.

Societal Effects Are a Major Factor for the Uptake of the Coronavirus Disease 2019 (COVID-19) Digital Contact Tracing App in The Netherlands

2.

Societal Effects Are a Major Factor for the Uptake of the Coronavirus Disease 2019 (COVID-19) Digital Contact Tracing App in The Netherlands

3.

Societal Effects Are a Major Factor for the Uptake of the Coronavirus Disease 2019 (COVID-19) Digital Contact Tracing App in The Netherlands

4.

Societal Effects Are a Major Factor for the Uptake of the Coronavirus Disease 2019 (COVID-19) Digital Contact Tracing App in The Netherlands

5.

Societal Effects Are a Major Factor for the Uptake of the Coronavirus Disease 2019 (COVID-19) Digital Contact Tracing App in The Netherlands

1.

SARS-CoV-2 antibodies in employees working in non-medical contact-intensive professions in the Netherlands: Baseline data from the prospective COco-study

2.

SARS-CoV-2 antibodies in employees working in non-medical contact-intensive professions in the Netherlands: Baseline data from the prospective COco-study

3.

SARS-CoV-2 antibodies in employees working in non-medical contact-intensive professions in the Netherlands: Baseline data from the prospective COco-study

4.

SARS-CoV-2 antibodies in employees working in non-medical contact-intensive professions in the Netherlands: Baseline data from the prospective COco-study

5.

SARS-CoV-2 antibodies in employees working in non-medical contact-intensive professions in the Netherlands: Baseline data from the prospective COco-study

6.

SARS-CoV-2 antibodies in employees working in non-medical contact-intensive professions in the Netherlands: Baseline data from the prospective COco-study

7.

SARS-CoV-2 antibodies in employees working in non-medical contact-intensive professions in the Netherlands: Baseline data from the prospective COco-study

1.

Substantial impact of the COVID-19 pandemic on the reported number of diagnosed chronic hepatitis C virus infections in the Netherlands, 2019–2021

2.

Substantial impact of the COVID-19 pandemic on the reported number of diagnosed chronic hepatitis C virus infections in the Netherlands, 2019–2021

3.

Substantial impact of the COVID-19 pandemic on the reported number of diagnosed chronic hepatitis C virus infections in the Netherlands, 2019–2021

4.

Substantial impact of the COVID-19 pandemic on the reported number of diagnosed chronic hepatitis C virus infections in the Netherlands, 2019–2021

1.

Additional file 1 of Creation of a pandemic memory by tracing COVID-19 infections and immunity in Luxembourg (CON-VINCE)

2.

Additional file 1 of Creation of a pandemic memory by tracing COVID-19 infections and immunity in Luxembourg (CON-VINCE)

3.

Additional file 1 of Creation of a pandemic memory by tracing COVID-19 infections and immunity in Luxembourg (CON-VINCE)

4.

Additional file 1 of Creation of a pandemic memory by tracing COVID-19 infections and immunity in Luxembourg (CON-VINCE)

5.

Additional file 1 of Creation of a pandemic memory by tracing COVID-19 infections and immunity in Luxembourg (CON-VINCE)

6.

Additional file 1 of Creation of a pandemic memory by tracing COVID-19 infections and immunity in Luxembourg (CON-VINCE)

7.

Additional file 1 of Creation of a pandemic memory by tracing COVID-19 infections and immunity in Luxembourg (CON-VINCE)

8.

Additional file 1 of Creation of a pandemic memory by tracing COVID-19 infections and immunity in Luxembourg (CON-VINCE)

9.

Additional file 1 of Creation of a pandemic memory by tracing COVID-19 infections and immunity in Luxembourg (CON-VINCE)

1.

SARS-CoV-2 transmission risk from asymptomatic carriers: Results from a mass screening programme in Luxembourg

2.

SARS-CoV-2 transmission risk from asymptomatic carriers: Results from a mass screening programme in Luxembourg

3.

SARS-CoV-2 transmission risk from asymptomatic carriers: Results from a mass screening programme in Luxembourg

4.

SARS-CoV-2 transmission risk from asymptomatic carriers: Results from a mass screening programme in Luxembourg